22 Jul Cellusion
Shin Hatou, M.D., Ph.D., CEO
Cellusion is a regenerative medicine startup founded by three professors at Keio University School of Medicine, Department of Ophthalmology in Japan. Cellusion has several unique technologies including a highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. The company’s lead program, CLS001 targeting Bullous Keratopathy, will start a first-in-human clinical study at Keio University Hospital soon. The company also has plans for several additional pipelines focusing on ophthalmologic diseases as well as other areas.